Abstract
The response of children to medicines differs to that of adults in both efficacy and toxicity. Very few medicines have been scientifically studied in children. European legislation will hopefully increase the number of clinical trials in children. In the UK, the establishment of a Medicines for Children Research Network should facilitate such trials. The development of paediatric clinical pharmacology, as a subspecialty of paediatrics will increase the number of specialists in this field. It is hoped that these developments will result in safer and more effective medicines for children.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
